The introduction of Tirzepatide represents a potential development in the management of the condition. This novel therapy, acting as a dual GIP and GLP-1 site stimulator, has demonstrated substantial improvements in glucose control and weight reduction in research settings. Experts are encouraged that Tirzepatide could provide a improved path for m